Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 33Fallopian Tube Neoplasms 21Endometrial Neoplasms 17Uterine Cervical Neoplasms 13Colorectal Neoplasms 12Neoplasm Metastasis 10Pancreatic Neoplasms 9Prostatic Neoplasms 8Melanoma 8Lung Neoplasms 8Carcinoma, Renal Cell 7Stomach Neoplasms 6Carcinosarcoma 6Carcinoma, Hepatocellular 6Carcinoma, Transitional Cell 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Papillomavirus Infections 4Esophageal Neoplasms 4Sarcoma 3Rectal Neoplasms 3Colonic Neoplasms 3Vulvar Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma, Kaposi 2Pelvic Neoplasms 2

Interventions

Hysterectomy 2ipatasertib 1entinostat 1Telemedicine 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Ovariectomy 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Magnetic Resonance Spectroscopy 1Interviews as Topic 1Health Promotion 1Exercise Test 1Educational Status 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Specimen Handling × Gynecologic × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡